January 15, 2026|Julian Gill
The company declined to provide its full response to the FDA but said it “addressed the agency’s feedback and will continue to regularly communicate with FDA about any remaining commitments.” … The FDA inspected the larger facility, known as a 503A compounding pharmacy, in November.
Read Full Article: https://www.houstonchronicle.com/news/houston-texas/health/article/houston-s-empower-pharmacy-repeat-quality-issues-21292606.php